Biogen Overview

  • Year Founded
  • 1978

Year Founded

  • Status
  • Public

  • Employees
  • 7,570

Employees

  • Stock Symbol
  • BIIB

Stock Symbol

  • Investments
  • 66

  • Share Price
  • $203.66
  • (As of Thursday Closing)

Biogen General Information

Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Contact Information

Website
www.biogen.com
Formerly Known As
Biogen Idec, Idec Pharmaceuticals Corp, Biogen Idec Inc, Biogen Idec Inc.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 225 Binney Street
  • Cambridge, MA 02142
  • United States
+1 (781) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biogen Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$203.66 $201.55 $200.65 - $319.76 $29.6B 145M 1.17M $8.02

Biogen Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 42,918,484 42,918,484 41,591,069 40,358,499
Revenue 9,835,600 9,835,600 10,173,400 10,981,700
EBITDA 1,762,000 1,762,000 4,267,500 2,475,500
Net Income 1,161,100 1,161,100 3,046,900 1,556,100
Total Assets 26,844,800 26,844,800 24,554,100 23,877,300
Total Debt 7,338,200 7,338,200 6,614,000 7,603,500
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.

Request a free trial

Biogen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer dru
Biotechnology
Cambridge, MA
7,570 As of 2023
000
0000 0000-00-00
000000&0

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labo
0000000000000
Pasadena, CA
000 As of 0000
00.000
00000000 00.000

000000

cing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000000000000
Mechelen, Belgium
000 As of 0000
00.000
000.00 0000-00-00
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biogen Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA 000 00.000 00000000 00.000
Galapagos (Biotechnology) Formerly VC-backed Mechelen, Belgium 000 00.000 000000000 00.000
AbbVie Corporation North Chicago, IL 00000 000.00 000000000 000.00
Moderna Formerly VC-backed Cambridge, MA 0000 00.00 00000000000 00.00
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
You’re viewing 5 of 32 competitors. Get the full list »

Biogen Patents

Biogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022346866-A1 Diroximel fumarate particles having improved flow properties and methods of making same Pending 17-Sep-2021
CA-3231790-A1 Diroximel fumarate particles having improved flow properties and methods of making same Pending 17-Sep-2021
US-20230131379-A1 Anti-transferrin receptor antibodies and uses thereof Active 01-Sep-2021 000000000
US-11827702-B2 Anti-transferrin receptor antibodies and uses thereof Active 01-Sep-2021 000000000 00
CA-3230796-A1 Anti-transferrin receptor antibodies and uses thereof Pending 01-Sep-2021 C07K16/2881
To view Biogen’s complete patent history, request access »

Biogen Executive Team (94)

Name Title Board Seat Contact Info
Christopher Viehbacher Chief Executive Officer, President & Board Member
Alisha Alaimo President, Head of North America
Michael Mcdonnell Executive Vice President, Chief Financial Officer & Member of the Executive Committee
Robin Kramer Chief Accounting Officer, Senior Vice President & Head of Global Business Services and Treasury
Susan Alexander JD Executive Vice President, Chief Legal Officer, Secretary & Member of the Executive Committee
You’re viewing 5 of 94 executive team members. Get the full list »

Biogen Board Members (23)

Name Representing Role Since
Caroline Dorsa Biogen Board Member & Chair, Audit Committee 000 0000
Christopher Viehbacher Biogen Chief Executive Officer, President & Board Member 000 0000
Eric Rowinsky MD Self Board Member & Member of the Corporate Governance Committee 000 0000
Jesus Mantas Self Board Member & Member of the Corporate Governance and Audit Committees 000 0000
Kasper Lage Ph.D Self Consultant & Chair of the Genetics and Analytics Advisory Panel 000 0000
You’re viewing 5 of 23 board members. Get the full list »

Biogen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Biogen‘s full profile, request access.

Request a free trial

Biogen Investments & Acquisitions (66)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Reata Pharmaceuticals 26-Sep-2023 0000000000 00.000 Drug Discovery 000000000
Autobahn Therapeutics 08-Sep-2022 00000 0000 000.00 Drug Discovery
Atalanta Therapeutics 11-Jan-2021 00000 0000 00000 Drug Discovery
SAGE Therapeutics 31-Dec-2020 0000 00000 Drug Discovery
Scribe Therapeutics 06-Oct-2020 Early Stage VC 0000 Discovery Tools (Healthcare)
You’re viewing 5 of 66 investments and acquisitions. Get the full list »

Biogen Subsidiaries (3)

Company Name Industry Location Founded
AliveGen USA Drug Discovery Thousand Oaks, CA 2014
TYSABRI Pharmaceuticals NC 0000
Biogen (Biosimilar Unit) Biotechnology MA
To view Biogen’s complete subsidiaries history, request access »

Biogen ESG

Risk Overview

Risk Rating

Updated July, 27, 2023

22.24 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,173

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 909

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 401

Rank

0.00

Percentile

To view Biogen’s complete esg history, request access »

Biogen Exits (33)

Company Name Exit Date Exit Type Exit Size Status Buyers
Samsung Bioepis 01-Nov-2018 000000000 00000000 00000 Completed
  • 000000
Solid Biosciences 30-Mar-2017 00000 00000 00 0000 Completed
  • 8 buyers
Yumanity Therapeutics 18-Feb-2016 00000 00000 00 0000 Completed
  • 7 buyers
Rodin Therapeutics 06-Jan-2016 00000 00000 00 000.00 Completed
  • 4 buyers
Solid GT 03-Nov-2015 Early Stage VC 000.00 Completed
  • 6 buyers
You’re viewing 5 of 33 exits. Get the full list »

Biogen FAQs

  • When was Biogen founded?

    Biogen was founded in 1978.

  • Who is the founder of Biogen?

    Charles Weissman, Heinz Schaller, Kenneth Murray, and Walter Gilbert Ph.D are the founders of Biogen.

  • Who is the CEO of Biogen?

    Christopher Viehbacher is the CEO of Biogen.

  • Where is Biogen headquartered?

    Biogen is headquartered in Cambridge, MA.

  • What is the size of Biogen?

    Biogen has 7,570 total employees.

  • What industry is Biogen in?

    Biogen’s primary industry is Biotechnology.

  • Is Biogen a private or public company?

    Biogen is a Public company.

  • What is Biogen’s stock symbol?

    The ticker symbol for Biogen is BIIB.

  • What is the current stock price of Biogen?

    As of 11-Apr-2024 the stock price of Biogen is $203.66.

  • What is the current market cap of Biogen?

    The current market capitalization of Biogen is $29.6B.

  • What is Biogen’s current revenue?

    The trailing twelve month revenue for Biogen is $9.8B.

  • Who are Biogen’s competitors?

    Arrowhead Pharmaceuticals, Galapagos (Biotechnology), AbbVie, Moderna, and Inovio Pharmaceuticals are some of the 32 competitors of Biogen.

  • What is Biogen’s annual earnings per share (EPS)?

    Biogen’s EPS for 12 months was $8.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »